Candesartan cilexetil in heart failure assessment of reduction in mortality and morbidity (CHARM Preserved)
Study identifier:SH-AHS-0007
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Candesartan cilexetil in heart failure assessment of reduction in mortality and morbidity. Clinical Study of Candesartan in Patients with heart failure and preserved left ventricular systolic function
Medical condition
Congestive Heart Failure
Phase
Phase 3
Healthy volunteers
No
Study drug
Candesartan, Placebo
Sex
All
Actual Enrollment
734
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jun 1999
Primary Completion Date: 01 May 2003
Study Completion Date: 01 May 2003
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 | - |
| Placebo Comparator: 2 | - |
Contacts
Investigators
Principal Investigator
Dr Salim Yusuf
-
